Menu
Log in
Forgot password


Log in
Forgot password

International Society for Antiviral Research


ICAR2020 Abstracts

back to schedule

Broadly neutralizing antibodies targeting HIV-1

Florian Klein, MD

Institute of Virology, University of Cologne, Germany


Broadly neutralizing antibodies (bNAbs) targeting HIV-1 can prevent infection in animal models and are under investigation for passive immunization in clinical trials. Moreover, bNAbs have been demonstrated to suppress viremia in HIV-1-infected individuals. While these results highlight the significant clinical potential of bNAbs, pre-existing and de novo HIV-1 resistance causes treatment failure and limits bNAb applications in humans. Strategies to overcome viral escape and to enhance the efficacy of bNAbs are therefore critical.


STAY CONNECTED

Join the ISAR mailing list to receive email announcements and updates on the Society and the International Conference on Antiviral Research (ICAR). 

SUBSCRIBE

FOLLOW ISAR

Linkedin

Powered by Wild Apricot Membership Software